The Jupiter trial: key findings, controversies, and implications.
Nissen
Steven E
SE
Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. nissens@ccf.org
D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D002309:Cardiology / Q000639:trends; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D003657:Decision Making; D019317:Evidence-Based Medicine; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use
D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein